Compare Cart
  • Japanese
  • Korean
  • Traditional Chinese
  • Simplified Chinese
Cover Image
Market Research Report
Product code 
1053812

Pulmonary Drug Delivery Systems Market by Product, Application (Asthma, Chronic Obstructive Pulmonary Diseases, and Cystic Fibrosis), and Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021--2030
Published: | Allied Market Research | 255 Pages | Delivery time: 2-3 business days

Price

Back to Top
Pulmonary Drug Delivery Systems Market by Product, Application (Asthma, Chronic Obstructive Pulmonary Diseases, and Cystic Fibrosis), and Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021--2030
Published: December 1, 2021
Allied Market Research
Content info: 255 Pages
Delivery time: 2-3 business days
  • Description
  • Table of Contents
  • List of Tables

The global pulmonary drug delivery systems market was valued at $49782.76 million in 2020, and is estimated to reach $ 91,128.61 million by 2030, growing at a CAGR of 6.08% from 2021 to 2030.

Targeted drug delivery system (TDDS) is a system of directing the drug directly into its targeted body site. Pulmonary drug delivery system (PDDS) is a type of targeted drug delivery system in which medicine is administered by inhalation method. PDDS has an advantage of quick onset of action over any other route of administration and plays an important role in asthma and chronic obstructive pulmonary disease (COPD). PDDS is a special type of device that is known as Aerosol. It is a pressurized dosage form containing one or more drugs which upon actuation emit a fine dispersed liquid and/or solid materials in gaseous medium. By device, PDDS is divided into nebulizer, metered dose inhaler, and dry powder inhaler.

The growth of the global pulmonary drug delivery market is driven by the rise in air pollution, and technical advancements. Furthermore, the rise in smoking culture is responsible for the increase in the number of COPD patients. Furthermore, air pollution causes inflammation of the bronchi & lungs, which is likely to enhance the market growth during the forecast period. According to the World Health Organization (WHO), in 2018, 9 out of 10 people inhale air that contain high levels of pollutants and an alarming death of 7 million people by ambient (outdoor) and household air pollution was noted. Pulmonary drug delivery has the advantage of quick onset time, which provides immediate relief in acute pulmonary spasms and COPD, emphasizing the importance of PDDS. The global PDDS market is expected to grow as it can be an alternative and effective targeted drug delivery option in the case of COVID-19. However, the high price of a pulmonary drug delivery system can limit the market growth. As per reports of CDC, the total treatment cost for asthma is $7 billion and For COPD is $5 billion, 2020.

The pulmonary drug delivery market is segmented on the basis of product, application, distribution channel, and region. By product, the market is divided into dry powder inhaler, metered dose inhaler, and nebulizer. The dry powder inhaler segment is further bifurcated into single dose inhaler and multi dose inhaler. The metered dose inhaler segment is further divided into manually-actuated pressurized inhaler and breath-actuated pressurized inhaler. The nebulizers segment is further classified into jet nebulizer, ultrasonic wave nebulizer, and vibrating mesh nebulizer.

By application, it is classified into asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and others. By distribution channel, it is categorized into retail pharmacies, hospital pharmacies, and e-commerce. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

  • The major companies profiled in the report include AstraZeneca plc, Boehringer Ingelheim Gmbh, GlaxoSmithKline plc, Novartis AG, Koninklijke Philips N.V., 3M company, Actelion Pharmaceuticals Ltd(Janssen), Clement, Clarke International, Briggs Healthcare and Aerogen

KEY BENEFITS FOR STAKEHOLDERS

  • The report provides an in-depth analysis of the global pulmonary drug delivery systems market size along with the current trends and future estimations to elucidate the imminent investment pockets.
  • It offers market analysis from 2021 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.
  • A comprehensive analysis on region assists to understand the regional market and facilitate the strategic business planning and determine prevailing opportunities.
  • The profiles and growth strategies of the key market players are thoroughly analyzed to understand the competitive outlook of the global pulmonary drug delivery systems market.

KEY MARKET SEGMENTS

By Product

  • Dry powder inhaler
  • Single dose inhaler
  • Multi dose inhaler
  • Metered dose inhaler
  • Manually-Actuated Pressurized Inhaler
  • Breath-Actuated Pressurized Inhaler
  • Nebulizer
  • Jet Nebulizer
  • Ultrasonic Wave Nebulizer
  • Vibrating Mesh Nebulizer

By Application

  • Asthma
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Cystic Fibrosis
  • Others

By Distribution Channel

  • Retail Pharmacies
  • Hospital Pharmacies
  • E-commerce

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

KEY MARKET PLAYERS

  • AstraZeneca plc
  • Boehringer Ingelheim Gmbh
  • GlaxoSmithKline plc
  • Novartis AG
  • Koninklijke Philips N.V.
  • 3M company
  • Janssen (Johnson & Johnson)
  • Clement Clarke International
  • Briggs Healthcare
  • Aerogen
Product Code: LI_182944 / A02607

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key Benefits for Stakeholders
  • 1.3.Key market segments
  • 1.4.Research methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO perspective

CHAPTER 3:MARKET LANDSCAPE

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
    • 3.2.2.Top winning strategies
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning, 2020
  • 3.5.Market dynamics
    • 3.5.1.Drivers
      • 3.5.1.1.Increase in prevalence of pulmonary diseases
      • 3.5.1.2.Increase in technological advancement in PDDS
      • 3.5.1.3.Increase in Government policies and awareness programs by private organization
    • 3.5.2.Restraint
      • 3.5.2.1.High cost of pulmonary drug delivery system
    • 3.5.3.Opportunity
      • 3.5.3.1.Increase in research and development in pulmonary drug delivery system.
    • 3.5.4.Impact analysis
  • 3.6.Impact analysis of COVID-19 on the pulmonary drug delivery systems market

CHAPTER 4:PULMONARY DRUG DELIVERY SYSTEM, BY PRODUCT

  • 4.1.Overview
    • 4.1.1.Market size and forecast
  • 4.2.Dry powder inhaler
    • 4.2.1.Key market trends, growth factors, and opportunities
    • 4.2.2.Dry powder inhaler, by type
      • 4.2.2.1.Market size and forecast
      • 4.2.2.2.Single Dose Inhaler
      • 4.2.2.2.1.Market size and forecast
      • 4.2.2.3.Multi Dose Inhaler
      • 4.2.2.3.1.Market size and forecast
    • 4.2.3.Market size and forecast, by region
    • 4.2.4.Market analysis, by country
  • 4.3.Metered dose inhaler
    • 4.3.1.Key market trends, growth factors, and opportunities
    • 4.3.2.Market size and forecast, by region
    • 4.3.3.Metered dose inhaler, by type
      • 4.3.3.1.Market size and forecast
      • 4.3.3.2.Manually actuated pressurized inhaler
      • 4.3.3.2.1.Market size and forecast
      • 4.3.3.3.Breath actuated pressurized inhaler
      • 4.3.3.3.1.Market size and forecast
    • 4.3.4.Market analysis, by country
  • 4.4.Nebulizer
    • 4.4.1.Key market trends, growth factors, and opportunities
    • 4.4.2.Nebulizer, by type
      • 4.4.2.1.Market size and forecast
      • 4.4.2.2.Jet nebulizer
      • 4.4.2.2.1.Market size and forecast
      • 4.4.2.3.Ultrasonic wave nebulizer
      • 4.4.2.3.1.Market size and forecast
      • 4.4.2.4.Vibrating mesh nebulizer
      • 4.4.2.4.1.Market size and forecast
    • 4.4.3.Market size and forecast, by region
    • 4.4.4.Market analysis, by country

CHAPTER 5:PULMONARY DRUG DELIVERY SYSTEM, BY APPLICATION

  • 5.1.Overview
    • 5.1.1.Market size and forecast
  • 5.2.Asthma
    • 5.2.1.Key market trends, growth factors, and opportunities
    • 5.2.2.Market size and forecast, by region
    • 5.2.3.Market analysis, by country
  • 5.3.Chronic obstructive pulmonary disease (COPD)
    • 5.3.1.Key market trends, growth factors, and opportunities
    • 5.3.2.Market size and forecast, by region
    • 5.3.3.Market analysis, by country
  • 5.4.Cystic fibrosis
    • 5.4.1.Key market trends, growth factors, and opportunities
    • 5.4.2.Market size and forecast, by region
    • 5.4.3.Market analysis, by country

CHAPTER 6:PULMONARY DRUG DELIVERY SYSTEM, BY DISTRIBUTION CHANNEL

  • 6.1.Overview
    • 6.1.1.Market size and forecast
  • 6.2.Retail pharmacies
    • 6.2.1.Key market trends, growth factors, and opportunities
    • 6.2.2.Market size and forecast, by region
    • 6.2.3.Market analysis, by country
  • 6.3.Hospital pharmacies
    • 6.3.1.Key market trends, growth factors, and opportunities
    • 6.3.2.Market size and forecast, by region
    • 6.3.3.Market analysis, by country
  • 6.4.E-commerce
    • 6.4.1.Key market trends, growth factors, and opportunities
    • 6.4.2.Market size and forecast, by region
    • 6.4.3.Market analysis, by country

CHAPTER 7:PULMONARY DRUG DELIVERY SYSTEM MARKET, BY REGION

  • 7.1.Overview
    • 7.1.1.Market size and forecast
  • 7.2.North America
    • 7.2.1.Key market trends, growth factors, and opportunities
    • 7.2.2.North America pulmonary drug delivery system market, by product
    • 7.2.3.North America pulmonary drug delivery system market, by application
    • 7.2.4.North America pulmonary drug delivery system market, by distribution channel
    • 7.2.5.Market size and forecast, by country
      • 7.2.5.1.U.S.
      • 7.2.5.1.1.U.S. pulmonary drug delivery system market, by product
      • 7.2.5.1.2.U.S. pulmonary drug delivery system market, by application
      • 7.2.5.1.3.U.S. pulmonary drug delivery system market, by distribution channel
      • 7.2.5.2.Canada
      • 7.2.5.2.1.Canada pulmonary drug delivery system market, by product
      • 7.2.5.2.2.Canada pulmonary drug delivery system market, by application
      • 7.2.5.2.3.Canada pulmonary drug delivery system market, by distribution channel
      • 7.2.5.3.Mexico
      • 7.2.5.3.1.Mexico pulmonary drug delivery system market, by product
      • 7.2.5.3.2.Mexico pulmonary drug delivery system market, by application
      • 7.2.5.3.3.Mexico pulmonary drug delivery system market, by distribution channel
  • 7.3.Europe
    • 7.3.1.Key market trends, growth factors, and opportunities
    • 7.3.2.Europe pulmonary drug delivery system market, by product
    • 7.3.3.Europe pulmonary drug delivery systems market, by application
    • 7.3.4.Europe pulmonary drug delivery systems market, by distribution channel
    • 7.3.5.Market size and forecast, by country
      • 7.3.5.1.Germany
      • 7.3.5.1.1.Germany pulmonary drug delivery system market, by product
      • 7.3.5.1.2.Germany pulmonary drug delivery system market, by application
      • 7.3.5.1.3.Germany pulmonary drug delivery system market, by distribution channel
      • 7.3.5.2.France
      • 7.3.5.2.1.France pulmonary drug delivery system market, by product
      • 7.3.5.2.2.France pulmonary drug delivery system market, by application
      • 7.3.5.2.3.France pulmonary drug delivery system market, by distribution channel
      • 7.3.5.3.UK
      • 7.3.5.3.1.UK pulmonary drug delivery system market, by product
      • 7.3.5.3.2.UK pulmonary drug delivery system market, by application
      • 7.3.5.3.3.UK pulmonary drug delivery system market, by distribution channel
      • 7.3.5.4.Italy
      • 7.3.5.4.1.Italy pulmonary drug delivery system market, by product
      • 7.3.5.4.2.Italy pulmonary drug delivery system market, by application
      • 7.3.5.4.3.Italy pulmonary drug delivery system market, by distribution channel
      • 7.3.5.5.Spain
      • 7.3.5.5.1.Spain pulmonary drug delivery systems market, by product
      • 7.3.5.5.2.Spain pulmonary drug delivery system market, by application
      • 7.3.5.5.3.Spain pulmonary drug delivery system market, by distribution channel
      • 7.3.5.6.Rest of Europe
      • 7.3.5.6.1.Rest of Europe pulmonary drug delivery system market, by product
      • 7.3.5.6.2.Rest of Europe pulmonary drug delivery system market, by application
      • 7.3.5.6.3.Rest of Europe pulmonary drug delivery system market , by distribution channel
  • 7.4.Asia-Pacific
    • 7.4.1.Key market trends, growth factors, and opportunities
    • 7.4.2.Asia-Pacific pulmonary drug delivery system market, by product
    • 7.4.3.Asia-Pacific pulmonary drug delivery system market, by application
    • 7.4.4.Asia-Pacific pulmonary drug delivery system market, by distribution channel
    • 7.4.5.Market size and forecast, by country
      • 7.4.5.1.Japan
      • 7.4.5.1.1.Japan pulmonary drug delivery system market, by product
      • 7.4.5.1.2.Japan pulmonary drug delivery system market, by application
      • 7.4.5.1.3.Japan pulmonary drug delivery system market, by distribution channel
      • 7.4.5.2.China
      • 7.4.5.2.1.China pulmonary drug delivery system market, by product
      • 7.4.5.2.2.China pulmonary drug delivery system market, by application
      • 7.4.5.2.3.China pulmonary drug delivery system market, by distribution channel
      • 7.4.5.3.Australia
      • 7.4.5.3.1.Australia pulmonary drug delivery system market, by product
      • 7.4.5.3.2.Australia pulmonary drug delivery system market, by application
      • 7.4.5.3.3.Australia pulmonary drug delivery system market, by distribution channel
      • 7.4.5.4.India
      • 7.4.5.4.1.India pulmonary drug delivery system market, by product
      • 7.4.5.4.2.India pulmonary drug delivery system market, by application
      • 7.4.5.4.3.India pulmonary drug delivery system market, by distribution channel
      • 7.4.5.5.South Korea
      • 7.4.5.5.1.South Korea pulmonary drug delivery system market, by product
      • 7.4.5.5.2.South Korea pulmonary drug delivery system market, by application
      • 7.4.5.5.3.South Korea pulmonary drug delivery system market, by distribution channel
      • 7.4.5.6.Rest of Asia-Pacific
      • 7.4.5.6.1.Rest of Asia-Pacific pulmonary drug delivery systems market, by product
      • 7.4.5.6.2.Rest of Asia-Pacific pulmonary drug delivery system market, by application
      • 7.4.5.6.3.Rest of Asia-Pacific pulmonary drug delivery system market, by distribution channel
  • 7.5.LAMEA
    • 7.5.1.Key market trends, growth factors, and opportunities
    • 7.5.2.LAMEA pulmonary drug delivery system market, by product
    • 7.5.3.LAMEA pulmonary drug delivery system market, by application
    • 7.5.4.LAMEA pulmonary drug delivery system market, by distribution channel
    • 7.5.5.Market size and forecast, by country
      • 7.5.5.1.Brazil
      • 7.5.5.1.1.Brazil pulmonary drug delivery system market, by product
      • 7.5.5.1.2.Brazil pulmonary drug delivery system market, by application
      • 7.5.5.1.3.Brazil pulmonary drug delivery system market, by distribution channel
      • 7.5.5.2.Saudi Arabia
      • 7.5.5.2.1.Saudi Arabia pulmonary drug delivery system market, by product
      • 7.5.5.2.2.Saudi Arabia pulmonary drug delivery system market, by application
      • 7.5.5.2.3.Saudi Arabia pulmonary drug delivery system market, by distribution channel
      • 7.5.5.3.South Africa
      • 7.5.5.3.1.South Africa pulmonary drug delivery system market, by product
      • 7.5.5.3.2.South Africa pulmonary drug delivery system market, by application
      • 7.5.5.3.3.South Africa pulmonary drug delivery system market, by distribution channel
      • 7.5.5.4.Rest of LAMEA
      • 7.5.5.4.1.Rest of LAMEA pulmonary drug delivery systems market, by product
      • 7.5.5.4.2.Rest of LAMEA pulmonary drug delivery system market, by application
      • 7.5.5.4.3.Rest of LAMEA pulmonary drug delivery system market, by distribution channel

CHAPTER 8:COMPANY PROFILES

  • 8.1.3M company
    • 8.1.1.Company overview
    • 8.1.2.Company snapshot
    • 8.1.3.Operating business segments
    • 8.1.4.Product portfolio
    • 8.1.5.Business performance
  • 8.2.Aerogen
    • 8.2.1.Company overview
    • 8.2.2.Company snapshot
    • 8.2.3.Product portfolio
  • 8.3.AstraZeneca plc
    • 8.3.1.Company overview
    • 8.3.2.Company snapshot
    • 8.3.3.Operating business segments
    • 8.3.4.Product portfolio
    • 8.3.5.Business performance
  • 8.4.Boehringer Ingelheim Gmbh
    • 8.4.1.Company overview
    • 8.4.2.Company snapshot
    • 8.4.3.Operating business segments
    • 8.4.4.Product portfolio
    • 8.4.5.Business performance
  • 8.5.Briggs Healthcare
    • 8.5.1.Company overview
    • 8.5.2.Company snapshot
    • 8.5.3.Operating business segments
    • 8.5.4.Product Portfolio
  • 8.6.Clement Clarke International
    • 8.6.1.Company overview
    • 8.6.2.Company snapshot
    • 8.6.3.Operating business segments
    • 8.6.4.Product portfolio
  • 8.7.GlaxoSmithKline plc
    • 8.7.1.Company overview
    • 8.7.2.Company snapshot
    • 8.7.3.Operating business segments
    • 8.7.4.Product portfolio
    • 8.7.5.Business performance
  • 8.8.Janssen
    • 8.8.1.Company overview
    • 8.8.2.Company snapshot
    • 8.8.3.Operating business segments
    • 8.8.4.Product portfolio
    • 8.8.5.Business performance
  • 8.9.Koninklijke Philips N.V. (Philips)
    • 8.9.1.Company overview
    • 8.9.2.Company snapshot
    • 8.9.3.Operating business segments
    • 8.9.4.Product portfolio
    • 8.9.5.Business performance
  • 8.10.Novartis AG
    • 8.10.1.Company overview
    • 8.10.2.Company snapshot
    • 8.10.3.Operating business segments
    • 8.10.4.Product portfolio
    • 8.10.5.Business performance

LIST OF TABLES

  • TABLE 01.GLOBAL PULMONARY DRUG DELIVERY SYSTEM MARKET, BY THERAPY, 2020-2030 ($MILLION)
  • TABLE 02.PULMONARY DRUG DELIVERY SYSTEM MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 03.PULMONARY DRUG DELIVERY SYSTEMS MARKET FOR DRY POWDER INHALER, BY REGION, 2020-2030 ($MILLION)
  • TABLE 04.PULMONARY DRUG DELIVERY SYSTEMS MARKET FOR METERED DOSE INHALER, BY REGION, 2020-2030 ($MILLION)
  • TABLE 05.PULMONARY DRUG DELIVERY SYSTEM MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 06.PULMONARY DRUG DELIVERY SYSTEM MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 07.PULMONARY DRUG DELIVERY SYSTEMS MARKET FOR NEBULIZER, BY REGION, 2020-2030 ($MILLION)
  • TABLE 08.GLOBAL PULMONARY DRUG DELIVERY SYSTEM MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 09.PULMONARY DRUG DELIVERY SYSTEMS MARKET FOR ASTHMA, BY REGION, 2020-2030 ($MILLION)
  • TABLE 10.PULMONARY DRUG DELIVERY SYSTEMS MARKET FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE, BY REGION, 2020-2030 ($MILLION)
  • TABLE 11.PULMONARY DRUG DELIVERY SYSTEMS MARKET FOR CYSTIC FIBROSIS, BY REGION, 2020-2030 ($MILLION)
  • TABLE 12.GLOBAL PULMONARY DRUG DELIVERY SYSTEM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 13.PULMONARY DRUG DELIVERY SYSTEMS MARKET FOR RETAIL PHARMACY, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 14.PULMONARY DRUG DELIVERY SYSTEMS MARKET FOR HOSPITAL PHARMACY, BY REGION, 2020-2030 ($MILLION)
  • TABLE 15.PULMONARY DRUG DELIVERY SYSTEMS MARKET FOR E-COMMERCE, BY REGION, 2020-2030 ($MILLION)
  • TABLE 16.PULMONARY DRUG DELIVERY SYSTEM MARKET, BY REGION, 2020-2030 ($MILLION)
  • TABLE 17.NORTH AMERICA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY PRODUCT, 2020-2030 ($MILLION)
  • TABLE 18.NORTH AMERICA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 19.NORTH AMERICA PULMONARY DRUG DELIVERY SYSTEM MARKET , BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 20.NORTH AMERICA PULMONARY DRUG DELIVERY SYSTEM MARKET WAS VALUED, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 21.U.S. PULMONARY DRUG DELIVERY SYSTEM MARKET, BY PRODUCT, 2020-2030 ($MILLION)
  • TABLE 22.U.S. PULMONARY DRUG DELIVERY SYSTEM MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 23.U.S. PULMONARY DRUG DELIVERY SYSTEM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 24.CANADA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY PRODUCT, 2020-2030 ($MILLION)
  • TABLE 25.CANADA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 26.CANADA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 27.MEXICO PULMONARY DRUG DELIVERY SYSTEM MARKET, BY PRODUCT, 2020-2030 ($MILLION)
  • TABLE 28.MEXICO PULMONARY DRUG DELIVERY SYSTEM MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 29.MEXICO PULMONARY DRUG DELIVERY SYSTEM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 30.EUROPE PULMONARY DRUG DELIVERY SYSTEM MARKET, BY PRODUCT, 2020-2030 ($MILLION)
  • TABLE 31.EUROPE PULMONARY DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 32.EUROPE PULMONARY DRUG DELIVERY SYSTEM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 33.EUROPE PULMONARY DRUG DELIVERY SYSTEMS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 34.GERMANY PULMONARY DRUG DELIVERY SYSTEM MARKET, BY PRODUCT, 2020-2030 ($MILLION)
  • TABLE 35.GERMANY PULMONARY DRUG DELIVERY SYSTEM MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 36.GERMANY PULMONARY DRUG DELIVERY SYSTEM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 37.FRANCE PULMONARY DRUG DELIVERY SYSTEM MARKET , BY PRODUCT, 2020-2030 ($MILLION)
  • TABLE 38.FRANCE PULMONARY DRUG DELIVERY SYSTEM MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 39.FRANCE PULMONARY DRUG DELIVERY SYSTEM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 40.UK PULMONARY DRUG DELIVERY SYSTEM MARKET, BY PRODUCT, 2020-2030 ($MILLION)
  • TABLE 41.UK PULMONARY DRUG DELIVERY SYSTEM MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 42.UK PULMONARY DRUG DELIVERY SYSTEM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 43.ITALY PULMONARY DRUG DELIVERY SYSTEM MARKET, BY PRODUCT, 2020-2030 ($MILLION)
  • TABLE 44.ITALY PULMONARY DRUG DELIVERY SYSTEM MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 45.ITALY PULMONARY DRUG DELIVERY SYSTEM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 46.SPAIN PULMONARY DRUG DELIVERY SYSTEM MARKET, BY PRODUCT, 2020-2030 ($MILLION)
  • TABLE 47.SPAIN PULMONARY DRUG DELIVERY SYSTEM MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 48.SPAIN PULMONARY DRUG DELIVERY SYSTEM MARKET BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 49.REST OF EUROPE PULMONARY DRUG DELIVERY SYSTEM MARKET , BY PRODUCT, 2020-2030 ($MILLION)
  • TABLE 50.REST OF EUROPE PULMONARY DRUG DELIVERY SYSTEM MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 51.REST OF EUROPE PULMONARY DRUG DELIVERY SYSTEM MARKET , BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 52.ASIA-PACIFIC PULMONARY DRUG DELIVERY SYSTEM MARKET, BY PRODUCT, 2020-2030 ($MILLION)
  • TABLE 53.ASIA-PACIFIC PULMONARY DRUG DELIVERY SYSTEM MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 54.ASIA-PACIFIC PULMONARY DRUG DELIVERY SYSTEM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 55.ASIA-PACIFIC PULMONARY DRUG DELIVERY SYSTEM MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 56.JAPAN PULMONARY DRUG DELIVERY SYSTEM MARKET, BY PRODUCT, 2020-2030 ($MILLION)
  • TABLE 57.JAPAN PULMONARY DRUG DELIVERY SYSTEM MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 58.JAPAN PULMONARY DRUG DELIVERY SYSTEM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 59.CHINA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY PRODUCT, 2020-2030 ($MILLION)
  • TABLE 60.CHINA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 61.CHINA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 62.AUSTRALIA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY PRODUCT 2020-2030 ($MILLION)
  • TABLE 63.AUSTRALIA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 64.AUSTRALIA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 65.INDIA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY PRODUCT, 2020-2030 ($MILLION)
  • TABLE 66.INDIA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 67.INDIA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 68.SOUTH KOREA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY PRODUCT, 2020-2030 ($MILLION)
  • TABLE 69.SOUTH KOREA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 70.SOUTH KOREA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 71.REST OF ASIA-PACIFIC PULMONARY DRUG DELIVERY SYSTEM MARKET, BY PRODUCT, 2020-2030 ($MILLION)
  • TABLE 72.REST OF ASIA-PACIFIC PULMONARY DRUG DELIVERY SYSTEM MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 73.REST OF ASIA-PACIFIC PULMONARY DRUG DELIVERY SYSTEM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 74.LAMEA PULMNARY DRUG DELIVERY SYSTEM MARKET, BY PRODUCT, 2020-2030 ($MILLION)
  • TABLE 75.LAMEA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 76.LAMEA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 77.LAMEA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 78.BRAZIL PULMONARY DRUG DELIVERY SYSTEM MARKET, BY PRODUCT, 2020-2030 ($MILLION)
  • TABLE 79.BRAZIL PULMONARY DRUG DELIVERY SYSTEM MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 80.BRAZIL PULMONARY DRUG DELIVERY SYSTEM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 81.SAUDI ARABIA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY PRODUCT, 2020-2030 ($MILLION)
  • TABLE 82.SAUDI ARABIA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 83.SAUDI ARABIA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 84.SOUTH AFRICA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY PRODUCT, 2020-2030 ($MILLION)
  • TABLE 85.SOUTH AFRICA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 86.SOUTH AFRICA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 87.REST OF LAMEA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY PRODUCT, 2020-2030 ($MILLION)
  • TABLE 88.REST OF LAMEA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 89.REST OF LAMEA PULMONARY DRUG DELIVERY SYSTEM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 90.3M: COMPANY SNAPSHOT
  • TABLE 91.3M: OPERATING SEGMENTS
  • TABLE 92.3M: PRODUCT PORTFOLIO
  • TABLE 93.AEROGEN: COMPANY SNAPSHOT
  • TABLE 94.AEROGEN: PRODUCT PORTFOLIO
  • TABLE 95.ASTRAZENECA: COMPANY SNAPSHOT
  • TABLE 96.ASTRAZENECA SEGMENTS
  • TABLE 97.ASTRAZENECA: PRODUCT PORTFOLIO
  • TABLE 98.BOEHRINGER INGELHEIM: COMPANY SNAPSHOT
  • TABLE 99.BOEHRINGER INGELHEIM SEGMENTS
  • TABLE 100.BOEHRINGER INGELHEIM: PRODUCT PORTFOLIO
  • TABLE 101.BRIGGS: COMPANY SNAPSHOT
  • TABLE 102.BRIGGS OPERATING SEGMENTS
  • TABLE 103.BRIGGS: PRODUCT PORTFOLIO
  • TABLE 104.CLEMENT CLARKE: COMPANY SNAPSHOT
  • TABLE 105.CLEMENT CLARKE: OPERATING SEGMENTS
  • TABLE 106.CLEMENT CLARKE: PRODUCT PORTFOLIO
  • TABLE 107.GSK: COMPANY SNAPSHOT
  • TABLE 108.GSK: OPERATING SEGMENTS
  • TABLE 109.GSK: PRODUCT PORTFOLIO
  • TABLE 110.JANSSEN: COMPANY SNAPSHOT
  • TABLE 111.JANSSEN: OPERATING SEGMENTS
  • TABLE 112.JANSSEN: PRODUCT PORTFOLIO
  • TABLE 113.PHILIPS: COMPANY SNAPSHOT
  • TABLE 114.PHILIPS: OPERATING SEGMENTS
  • TABLE 115.PHILIPS: PRODUCT PORTFOLIO
  • TABLE 116.NOVARTIS: COMPANY SNAPSHOT
  • TABLE 117.NOVARTIS: OPERATING SEGMENTS
  • TABLE 118.NOVARTIS: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01.PULMONARY DRUG DELIVERY SYSTEM MARKET SEGMENTATION
  • FIGURE 02.TOP INVESTMENT POCKETS
  • FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2018-2021
  • FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018-2021
  • FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2018-2021
  • FIGURE 06.MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 07.MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 08.MODERATE THREAT OF SUBSTITUTES
  • FIGURE 09.MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 10.MODERATE INTENSITY OF RIVALRY
  • FIGURE 11.TOP PLAYER POSITIONING, 2020
  • FIGURE 12.IMPACT ANALYSIS
  • FIGURE 13.COMPARATIVE ANALYSIS OF PULMONARY DRUG DELIVERY SYSTMES MARKET FOR DRY POWDER INHALER, BY COUNTRY, 2020-2030 (%)
  • FIGURE 14.COMPARATIVE ANALYSIS OF PULMONARY DRUG DELIVERY SYSTEMS MARKET FOR METERED DOSE INHALER, BY COUNTRY, 2020-2030 (%)
  • FIGURE 15.COMPARATIVE ANALYSIS OF PULMONARY DRUG DELIVERY SYSTEMS MARKET FOR NEBULIZER, BY COUNTRY, 2020-2030 (%)
  • FIGURE 16.COMPARATIVE ANALYSIS OF PULMONARY DRUG DELIVERY SYSTEMS MARKET FOR ASTHMA, BY COUNTRY, 2020-2030 (%)
  • FIGURE 17.COMPARATIVE ANALYSIS OF PULMONARY DRUG DELIVERY SYSTEMS MARKET FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE, BY COUNTRY, 2020-2030 (%)
  • FIGURE 18.COMPARATIVE ANALYSIS OF PULMONARY DRUG DELIVERY SYSTEMS MARKET FOR CYSTIC FIBROSIS, BY COUNTRY, 2020-2030 (%)
  • FIGURE 19.COMPARATIVE ANALYSIS OF PULMONARY DRUG DELIVERY SYSTEMS MARKET FOR RETAIL PHARMACY, BY COUNTRY, 2020-2030 (%)
  • FIGURE 20.COMPARATIVE ANALYSIS OF PULMONARY DRUG DELIVERY SYSTEMS MARKET FOR HOSPITAL PHARMACY, BY COUNTRY, 2020-2030 (%)
  • FIGURE 21.COMPARATIVE ANALYSIS OF PULMONARY DRUG DELIVERY SYSTEMS MARKET FOR E-COMMERCE, BY COUNTRY, 2020-2030 (%)
  • FIGURE 22.3M: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 23.3M: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 24.3M: REVENUE SHARE BY REGION, 2020(%)
  • FIGURE 25.ASTRAZENECA: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 26.ASTRAZENECA: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 27.ASTRAZENECA: REVENUE SHARE BY REGION, 2020(%)
  • FIGURE 28.BOEHRINGER INGELHEIM: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 29.BOEHRINGER INGELHEIM: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 30.BOEHRINGER INGELHEIM: REVENUE SHARE BY REGION, 2020(%)
  • FIGURE 31.GSK: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 32.GSK: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 33.GSK REVENUE SHARE BY REGION, 2020(%)
  • FIGURE 34.JANSSEN: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 35.JANSSEN: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 36.JANSSEN: REVENUE SHARE BY REGION, 2020(%)
  • FIGURE 37.PHILIPS: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 38.PHILIPS: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 39.PHILIPS: REVENUE SHARE BY REGION, 2020(%)
  • FIGURE 40.NOVARTIS: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 41.NOVARTIS: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 42.NOVARTIS: REVENUE SHARE BY REGION, 2020(%)